← Back
$VRNA All transactions

Verona Pharma plc

M 10b5-1 Plan

$ Value

$0

Shares

86,064

Price

$0

Filed

May 1

Insider

Name

Rickard Kathleen A.

Title

Chief Medical Officer

CIK

0001836883

Roles

Officer

Transaction Details

Transaction Date

2025-04-29

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

167,056

Footnotes

Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. | The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into on May 14, 2021 solely with the intent to cover taxes in connection with the vesting of Restricted Share Units. | The price reported represents the sale price of the ADSs divided by eight (8). | Consists of (i) 722,488 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 90,311 ADSs); and (ii) 1,938,168 Ordinary Shares underlying 242,271 ADSs. | Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. | The RSUs were earned upon the satisfaction of the performance condition in connection with the Issuer's first commercial sale of ensifentrine. Following the satisfaction of the performance condition, the RSUs vest in equal quarterly installments on each of May 1, 2025, August 1, 2025, November 1, 2025, February 1, 2026, May 1, 2026 and August 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. | The RSUs were earned upon the determination by the Board of Directors of the Issuer (the "Determination Date") that certain performance metrics related to Q1 2025 had been achieved. The RSUs vested as to 34% of the total shares on the Determination Date, and vest as to the remainder of the shares in equal quarterly installments over a two year period on each of August 1, November 1, February 1 and May 1, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Filing Info

Accession No.

0001104659-25-043646

Form Type

4

Issuer CIK

0001657312

Rickard Kathleen A.'s History

Date Ticker Type Value
2025-10-07 VRNA D
2025-10-07 VRNA M
2025-10-07 VRNA D
2025-10-07 VRNA M
2025-10-07 VRNA M
2025-10-07 VRNA M
2025-10-07 VRNA A
2025-10-07 VRNA M
2025-10-07 VRNA D
2025-10-07 VRNA D

Other Insiders at VRNA (90d)

No other insider activity at this issuer in the last 90 days.